leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals combining science and cannabis to create 'affordable medicines'

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer tells Proactive's Andrew Scott they have two investigational medicinal products targeting epilepsy and dementia as well as Alzheimer’s disease. These include CannEpil®, an oral oil solution treatment for refractory epilepsy and CogniCann®, an oral spray for relief of dementia symptoms. MGC's also recently confirmed the effective immunological activity for the use of another one of their products - ArtemiC - as an immune-modulatory agent for the treatment of COVID-19. They're currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial which is taking place in Israel with an additional site in India.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

ASX:MXC
Market: ASX
Market Cap: $39.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment...

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the...

1 day, 10 hours ago

2 min read